ES2778950T3 - Triazinas para el tratamiento de enfermedades protozoarias - Google Patents

Triazinas para el tratamiento de enfermedades protozoarias Download PDF

Info

Publication number
ES2778950T3
ES2778950T3 ES13802596T ES13802596T ES2778950T3 ES 2778950 T3 ES2778950 T3 ES 2778950T3 ES 13802596 T ES13802596 T ES 13802596T ES 13802596 T ES13802596 T ES 13802596T ES 2778950 T3 ES2778950 T3 ES 2778950T3
Authority
ES
Spain
Prior art keywords
composition
toltrazuril
body weight
intramuscular
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13802596T
Other languages
English (en)
Spanish (es)
Inventor
Hamadi Karembe
Roman Krejci
Jérôme Guyonnet
Hannelie Cilliers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47351540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2778950(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Application granted granted Critical
Publication of ES2778950T3 publication Critical patent/ES2778950T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
ES13802596T 2012-12-07 2013-12-06 Triazinas para el tratamiento de enfermedades protozoarias Active ES2778950T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306546.8A EP2740469A1 (en) 2012-12-07 2012-12-07 New treatments with triazines
PCT/EP2013/075755 WO2014086958A1 (en) 2012-12-07 2013-12-06 New treatments with triazines

Publications (1)

Publication Number Publication Date
ES2778950T3 true ES2778950T3 (es) 2020-08-12

Family

ID=47351540

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13802596T Active ES2778950T3 (es) 2012-12-07 2013-12-06 Triazinas para el tratamiento de enfermedades protozoarias

Country Status (23)

Country Link
US (1) US9877969B2 (hr)
EP (3) EP2740469A1 (hr)
JP (1) JP6125034B2 (hr)
KR (1) KR102253497B1 (hr)
CN (3) CN104981233A (hr)
AU (1) AU2013353982B2 (hr)
BR (3) BR122021005310B1 (hr)
CA (1) CA2892886C (hr)
CL (1) CL2015001563A1 (hr)
CY (1) CY1123190T1 (hr)
DK (1) DK2928454T3 (hr)
ES (1) ES2778950T3 (hr)
FR (1) FR20C1044I2 (hr)
HR (1) HRP20200630T1 (hr)
HU (2) HUE049950T2 (hr)
MX (1) MX2015007128A (hr)
NL (1) NL301064I2 (hr)
PH (1) PH12015501220A1 (hr)
PL (1) PL2928454T3 (hr)
PT (1) PT2928454T (hr)
RU (1) RU2696265C2 (hr)
SI (1) SI2928454T1 (hr)
WO (1) WO2014086958A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
EP2740470A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740492A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies
EP3578182A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
US4493826A (en) * 1982-01-25 1985-01-15 Schering Corporation Gentamicin-gleptoferron compositions
DE3300793A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
US5219853A (en) 1983-01-12 1993-06-15 Bayer Aktiengesellschaft Agent for coccidiosis
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
JPH0776524A (ja) * 1993-07-13 1995-03-20 Takeda Chem Ind Ltd 動物用抗貧血剤
DE19603954C2 (de) 1996-02-05 2003-04-17 Wagon Automotive Gmbh Prallträger für ein Kraftfahrzeug
DE19603984A1 (de) 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
DE19824483A1 (de) 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
EP1119255A4 (en) * 1998-10-08 2009-04-15 New Ace Res Company NEW COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF PROTOCOL DISEASES
AU4034800A (en) 1999-10-08 2001-04-23 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
JP4904283B2 (ja) 2004-12-01 2012-03-28 アキュショット インク 無針注射器
DK2023981T3 (da) 2006-06-07 2020-04-06 Acushot Inc Ladningsmekanisme til en nålefri injektor
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007025908A1 (de) * 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
TW201006515A (en) 2008-03-07 2010-02-16 Pharmajet Inc Intradermal injector and uses thereof
SI22751A (sl) 2008-04-03 2009-10-31 Krka, D.D., Novo Mesto Toltrazuril z izboljĺ animi lastnostmi za raztapljanje
FR2946882B1 (fr) 2009-06-18 2011-08-26 Ceva Sante Animale Suspension veterinaire gelifiee de fer
CN101947201B (zh) 2010-09-08 2011-12-28 洛阳惠中兽药有限公司 兽药纳米混悬剂及其制备方法与应用
CN102512366A (zh) 2011-12-28 2012-06-27 广州市和生堂动物药业有限公司 妥曲珠利悬浮乳剂及其制备方法
CN102743334A (zh) 2012-07-30 2012-10-24 郑州后羿制药有限公司 一种妥曲珠利注射剂及其制备方法
EP2740470A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP2740492A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies

Also Published As

Publication number Publication date
PT2928454T (pt) 2020-04-23
US9877969B2 (en) 2018-01-30
HRP20200630T1 (hr) 2020-07-10
PH12015501220B1 (en) 2015-08-17
CN113144202A (zh) 2021-07-23
EP2740469A1 (en) 2014-06-11
JP2016501252A (ja) 2016-01-18
HUE049950T2 (hu) 2020-11-30
US20150313905A1 (en) 2015-11-05
EP2928454B1 (en) 2020-03-18
FR20C1044I2 (fr) 2021-10-15
FR20C1044I1 (hr) 2020-10-30
EP2928454A1 (en) 2015-10-14
JP6125034B2 (ja) 2017-05-10
HUS2000037I1 (hu) 2020-10-28
MX2015007128A (es) 2015-10-14
KR20150104565A (ko) 2015-09-15
EP3721869A1 (en) 2020-10-14
BR122021005311B1 (pt) 2022-01-25
BR122021005310B1 (pt) 2022-01-25
CN104981233A (zh) 2015-10-14
NL301064I2 (nl) 2021-03-03
AU2013353982A1 (en) 2015-06-11
CA2892886C (en) 2021-09-07
WO2014086958A1 (en) 2014-06-12
BR112015013182A2 (pt) 2017-07-11
KR102253497B1 (ko) 2021-05-21
AU2013353982B2 (en) 2018-01-04
DK2928454T3 (da) 2020-03-30
CL2015001563A1 (es) 2015-10-23
PH12015501220A1 (en) 2015-08-17
CN112370454A (zh) 2021-02-19
SI2928454T1 (sl) 2020-07-31
PL2928454T3 (pl) 2020-08-24
CY1123190T1 (el) 2021-10-29
CA2892886A1 (en) 2014-06-12
RU2696265C2 (ru) 2019-08-01
RU2015127025A (ru) 2017-01-12

Similar Documents

Publication Publication Date Title
ES2778950T3 (es) Triazinas para el tratamiento de enfermedades protozoarias
ES2761574T3 (es) Tratamiento de la coccidiosis con composiciones de triazina intramusculares
RU2484825C9 (ru) Трансдермальное применение триазинов для борьбы с инфекциями кокцидий
RU2826432C2 (ru) Лечение кокцидиоза внутримышечными композициями триазина